TY - JOUR
T1 - A genetic variant of the CD14 C-159T in patients with functional dyspepsia (FD) in Japanese subjects
AU - Tahara, Tomomitsu
AU - Arisawa, Tomiyasu
AU - Shibata, Tomoyuki
AU - Nakamura, Masakatsu
AU - Wang, Fangyu
AU - Yoshioka, Daisuke
AU - Okubo, Masaaki
AU - Maruyama, Naoko
AU - Kamiya, Yoshio
AU - Nakamura, Masahiko
AU - Fujita, Hiroshi
AU - Nagasaka, Mitsuo
AU - Iwata, Masami
AU - Takahama, Kazuya
AU - Watanabe, Makoto
AU - Hirata, Ichiro
AU - Nakano, Hiroshi
PY - 2008/3
Y1 - 2008/3
N2 - Inflammatory changes in the gastric mucosa are commonly observed in Japanese patients with functional dyspepsia (FD). However, detailed data regarding the relationship between the genetic regulatory factors of inflammation and FD are not available. CD14 is an important mediator of the inflammatory response in the first line of host defense by recognition of Lipopolysaccharide (LPS). We aimed to investigate the association between CD14 promoter C-159T polymorphism and FD in a Japanese population. 108 patients with FD and 99 non-dyspeptic subjects enrolled in this study. Dyspeptic symptoms were divided according to Rome III criteria. CD14 gene C-159T polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism. In the non-dyspeptics, the CD14 genotype distribution was 28CC (28.3%), 51CT (51.5%), 21TT (21.2%). Meanwhile, the CD14 genotype distribution in FD was 31CC (28.4%), 56CT (51.4%), 22TT (20.2%). The genotype distribution was not significantly different. There was no significant difference between two groups in the genotype distribution. We did not found any association between CD14 genotypes and dyspeptic patients in different gender and Helicobacter pylori infection status. No significant association was also found between CD14 polymorphism and any of different subtypes of FD according to Rome 111 while there was a weak correlation between TT genotype and PDS in male subjects (TT vs others, OR = 3.18, 95% CI = 0.98-10.26, p = 0.06). In conclusion, our results suggest that CD14 polymorphism is unlikely to associate with susceptibility of dyspeptic symptoms. The role of inflammation related-gene polymorphisms to the development of dyspepsia needs to further evaluation.
AB - Inflammatory changes in the gastric mucosa are commonly observed in Japanese patients with functional dyspepsia (FD). However, detailed data regarding the relationship between the genetic regulatory factors of inflammation and FD are not available. CD14 is an important mediator of the inflammatory response in the first line of host defense by recognition of Lipopolysaccharide (LPS). We aimed to investigate the association between CD14 promoter C-159T polymorphism and FD in a Japanese population. 108 patients with FD and 99 non-dyspeptic subjects enrolled in this study. Dyspeptic symptoms were divided according to Rome III criteria. CD14 gene C-159T polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism. In the non-dyspeptics, the CD14 genotype distribution was 28CC (28.3%), 51CT (51.5%), 21TT (21.2%). Meanwhile, the CD14 genotype distribution in FD was 31CC (28.4%), 56CT (51.4%), 22TT (20.2%). The genotype distribution was not significantly different. There was no significant difference between two groups in the genotype distribution. We did not found any association between CD14 genotypes and dyspeptic patients in different gender and Helicobacter pylori infection status. No significant association was also found between CD14 polymorphism and any of different subtypes of FD according to Rome 111 while there was a weak correlation between TT genotype and PDS in male subjects (TT vs others, OR = 3.18, 95% CI = 0.98-10.26, p = 0.06). In conclusion, our results suggest that CD14 polymorphism is unlikely to associate with susceptibility of dyspeptic symptoms. The role of inflammation related-gene polymorphisms to the development of dyspepsia needs to further evaluation.
UR - http://www.scopus.com/inward/record.url?scp=46249111610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46249111610&partnerID=8YFLogxK
U2 - 10.3164/jcbn.2008015
DO - 10.3164/jcbn.2008015
M3 - Article
C2 - 18385826
AN - SCOPUS:46249111610
SN - 0912-0009
VL - 42
SP - 104
EP - 110
JO - Journal of Clinical Biochemistry and Nutrition
JF - Journal of Clinical Biochemistry and Nutrition
IS - 2
ER -